ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer
-
Published:2024-09
Issue:
Volume:
Page:
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Van Gorp T., Cibula D.ORCID, Lv W., Backes F.ORCID, Ortaç F., Hasegawa K., Lindemann K., Savarese A., Laenen A.ORCID, Kim Y.M., Bodnar L., Barretina-Ginesta M.-P., Gilbert L., Pothuri B., Chen X., Flores M.B.ORCID, Levy T., Colombo N., Papadimitriou C., Buchanan T., Hanker L.C., Eminowicz G., Rob L., Black D., Lichfield J., Lin G., Orlowski R., Keefe S., Lortholary A., Slomovitz B.ORCID
Reference41 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021 2. Global, regional, and national burden of endometrial cancer, 1990-2017: results from the Global Burden of Disease Study, 2017;Zhang;Front Oncol,2019 3. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Oaknin;Ann Oncol,2022 4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Uterine Neoplasms. Version 2.2024. March 6, 2024. 5. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up;Colombo;Ann Oncol,2016
|
|